Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;26(17):4635-4644.
doi: 10.1111/jcmm.17488. Epub 2022 Aug 19.

The efficacy of coenzyme Q10 treatment in alleviating the symptoms of primary coenzyme Q10 deficiency: A systematic review

Affiliations

The efficacy of coenzyme Q10 treatment in alleviating the symptoms of primary coenzyme Q10 deficiency: A systematic review

Ying Wang et al. J Cell Mol Med. 2022 Sep.

Abstract

Coenzyme Q10 (CoQ10 ) is necessary for mitochondrial electron transport. Mutations in CoQ10 biosynthetic genes cause primary CoQ10 deficiency (PCoQD) and manifest as mitochondrial disorders. It is often stated that PCoQD patients can be treated by oral CoQ10 supplementation. To test this, we compiled all studies describing PCoQD patients up to May 2022. We excluded studies with no data on CoQ10 treatment, or with insufficient description of effectiveness. Out of 303 PCoQD patients identified, we retained 89 cases, of which 24 reported improvements after CoQ10 treatment (27.0%). In five cases, the patient's condition was reported to deteriorate after halting of CoQ10 treatment. 12 cases reported improvement in the severity of ataxia and 5 cases in the severity of proteinuria. Only a subjective description of improvement was reported for 4 patients described as responding. All reported responses were partial improvements of only some symptoms. For PCoQD patients, CoQ10 supplementation is replacement therapy. Yet, there is only very weak evidence for the efficacy of the treatment. Our findings, thus, suggest a need for caution when seeking to justify the widespread use of CoQ10 for the treatment of any disease or as dietary supplement.

Keywords: CoQ biosynthesis; CoQ10 supplementation; coenzyme Q; mitochondrial disorders; primary CoQ10 deficiency; ubiquinone.

PubMed Disclaimer

Conflict of interest statement

SH and YW have received royalty payment from Clarus Therapeutics Holdings. SH also consults for Clarus Therapeutics Holdings.

Figures

FIGURE 1
FIGURE 1
CoQ10 in the mitochondria, pathology of CoQ10 deficiency and oral supplementation. (A) The final steps of CoQ10 biosynthesis are carried out in the inner mitochondrial membrane. The CoQ10 biosynthetic pathway includes both enzymes (in blue) and structural or regulatory components (in purple). Only the numbers in their names are shown for COQ proteins (COQ2‐7, COQ8A, COQ8B and COQ9). They are known to form a large complex, the CoQ biosynthetic complex or CoQ‐synthome. COQ10A and COQ10B whose functions are uncertain and not known to be part of the complex are not shown. The most essential function of CoQ10 is to transport electrons in the mitochondrial respiratory chain. Although CoQ10 is found in the mitochondrial membrane, in the figure this is not shown for clarity. (B) Primary CoQ10 deficiency predominantly manifests as mitochondrial disorder, with organs with high energy needs being most often affected. (C) Intestinal absorption of CoQ10 is thought to occur through the formation of mixed micelles with other dietary lipids. Once inside the enterocytes, CoQ10 is incorporated into chylomicrons (CM), which are transported via the lymphatics to the blood circulation. Because of its extreme hydrophobicity and its relatively large size, the absorption of orally administered CoQ10 has been reported to be poor
FIGURE 2
FIGURE 2
Flow diagram for identification and selection of primary CoQ10 deficiency patients
FIGURE 3
FIGURE 3
Violin plots of CoQ10 treatment dose and duration. (A) Two graphs are shown for dosage comparisons because CoQ10 treatment dosages were reported in 2 different units (mg/kg/day and mg/day). (B) Comparison of CoQ10 treatment duration. (C) Disease durations before CoQ10 treatment. ns: not significant (Student's t‐test). Sample sizes are indicated on the graphs. Note that the measures plotted in these graphs only include the patients for which the information was provided in the case reports, which is why the sample sizes are different

Similar articles

Cited by

References

    1. Wang Y, Hekimi S. Understanding ubiquinone. Trends Cell Biol. 2016;26(5):367‐378. - PubMed
    1. Quinzii CM, Luna‐Sanchez M, Ziosi M, Hidalgo‐Gutierrez A, Kleiner G, Lopez LC. The role of sulfide oxidation impairment in the pathogenesis of primary CoQ deficiency. Front Physiol. 2017;8:525. - PMC - PubMed
    1. Lenaz G, Genova ML. Structure and organization of mitochondrial respiratory complexes: a new understanding of an old subject. Antioxid Redox Signal. 2010;12(8):961‐1008. - PubMed
    1. Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr. 2001;20(6):591‐598. - PubMed
    1. Morre DJ, Morre DM. Non‐mitochondrial coenzyme Q. Biofactors. 2011;37(5):355‐360. - PubMed

Publication types

Supplementary concepts

Grants and funding